Merck Announced KEYTRUDA Plus Padcev Reduced Risk of Death By More Than Half Versus Chemotherapy In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer
Portfolio Pulse from Charles Gross
Merck (NYSE:MRK) announced results from the Phase 3 KEYNOTE-A39 trial, conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA plus Padcev. The combination significantly prolonged overall survival by 53% compared to chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. The results were selected for presentation at the European Society for Medical Oncology Congress 2023.
October 22, 2023 | 2:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA plus Padcev showed significant improvement in overall survival in urothelial carcinoma patients, potentially boosting the company's market position in cancer treatment.
The positive results from the Phase 3 trial of KEYTRUDA plus Padcev could enhance Merck's reputation and market position in the field of cancer treatment. This could potentially lead to increased demand for these drugs, positively impacting Merck's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100